{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:42:55Z","timestamp":1740184975842,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:p>Grundstein der Behandlung der leichten Colitis ulcerosa ist nach wie vor die perorale oder topische (rektale) Anwendung von 5\u2011Aminosalicylaten (5-ASA). H\u00e4ufig werden bei der leichten Colitis ulcerosa 5\u2011ASA-Pr\u00e4parate nur peroral verabreicht. Dabei zeigen Studiendaten, dass bei der Proctitis ulcerosa und der linksseitigen Kolitis rektale 5\u2011ASA-Applikationen sogar wirksamer sind als die orale Verabreichung. In einem n\u00e4chsten Schritt sollten steroidhaltige topische Therapien eingesetzt werden. Beim leichten Morbus Crohn kommen prim\u00e4r topische Steroide wie Budesonid zum Einsatz. Bei symptomfreien Patienten ist aber umstritten, ob eine Therapie notwendig ist. Es fehlt nach wie vor die Evidenz, die nachweisen w\u00fcrde, dass die aggressivere Behandlung (mit Immunsuppressiva, Biologika oder \u201esmall molecules\u201c) bei diesen Patienten einen Vorteil f\u00fcr den Langzeitverlauf hat. In den meisten Leitlinien wird der Einsatz von 5\u2011ASA bei leichtem Morbus Crohn kritisch gesehen. Dennoch existiert eine gewisse Evidenz f\u00fcr eine ausreichend hoch dosierte Therapie mit 5\u2011ASA, wobei man sich der limitierten Wirksamkeit bewusst sein muss. F\u00fcr den postoperativen Einsatz von 5\u2011ASA bei einem leichten Rezidiv gibt es dagegen klare Evidenz.<\/jats:p>","DOI":"10.1007\/s00108-024-01840-x","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T16:26:01Z","timestamp":1734971161000},"page":"15-21","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effiziente Therapie des leichten Morbus Crohn und der leichten Colitis ulcerosa","Efficient treatment of mild Crohn\u2019s disease and mild ulcerative colitis"],"prefix":"10.1007","volume":"66","author":[{"given":"Gerhard","family":"Rogler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"1840_CR1","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/ecco-jcc\/jjab010","volume":"15","author":"B Barberio","year":"2021","unstructured":"Barberio\u00a0B, Segal\u00a0JP, Quraishi\u00a0MN et\u00a0al (2021) Efficacy of Oral, Topical, or Combined Oral and Topical 5\u2011Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. J\u00a0Crohns Colitis 15:1184\u20131196","journal-title":"J Crohns Colitis"},{"key":"1840_CR2","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1111\/bcp.14051","volume":"85","author":"S Bonovas","year":"2019","unstructured":"Bonovas\u00a0S, Nikolopoulos\u00a0GK, Piovani\u00a0D et\u00a0al (2019) Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A\u00a0systematic review and network meta-analysis. Br J Clin Pharmacol 85:2244\u20132254","journal-title":"Br J Clin Pharmacol"},{"key":"1840_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/ecco-jcc\/jjy154","volume":"13","author":"J Burisch","year":"2019","unstructured":"Burisch\u00a0J, Katsanos\u00a0KH, Christodoulou\u00a0DK et\u00a0al (2019) Natural disease course of ulcerative colitis during the first five years of follow-up in a\u00a0European population-based inception cohort-an Epi-IBD study. J\u00a0Crohns Colitis 13:198\u2013208","journal-title":"J Crohns Colitis"},{"key":"1840_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/gutjnl-2017-315568","volume":"68","author":"J Burisch","year":"2019","unstructured":"Burisch\u00a0J, Kiudelis\u00a0G, Kupcinskas\u00a0L et\u00a0al (2019) Natural disease course of Crohn\u2019s disease during the first 5\u00a0years after diagnosis in a\u00a0European population-based inception cohort: an Epi-IBD study. Gut 68:423\u2013433","journal-title":"Gut"},{"key":"1840_CR5","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1097\/MIB.0000000000001158","volume":"23","author":"S Coward","year":"2017","unstructured":"Coward\u00a0S, Kuenzig\u00a0ME, Hazlewood\u00a0G et\u00a0al (2017) Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn\u2019s Disease: A\u00a0Bayesian Network Meta-analysis: Republished. Inflamm Bowel Dis 23:E26\u2013E37","journal-title":"Inflamm Bowel Dis"},{"key":"1840_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/17474124.2024.2397650","volume":"18","author":"F D\u2019Amico","year":"2024","unstructured":"D\u2019Amico\u00a0F, Magro\u00a0F, Dignass\u00a0A et\u00a0al (2024) Practical management of mild-to-moderate ulcerative colitis: an international expert consensus. Expert Rev Gastroenterol Hepatol 18:421\u2013430","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1840_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/BF00542120","volume":"25","author":"C Fischer","year":"1983","unstructured":"Fischer\u00a0C, Maier\u00a0K, Stumpf\u00a0E et\u00a0al (1983) Disposition of 5\u2011aminosalicylic acid, the active metabolite of sulphasalazine, in man. Eur J Clin Pharmacol 25:511\u2013515","journal-title":"Eur J Clin Pharmacol"},{"key":"1840_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/ajg.2011.410","volume":"107","author":"AC Ford","year":"2012","unstructured":"Ford\u00a0AC, Khan\u00a0KJ, Achkar\u00a0JP, Moayyedi\u00a0P (2012) Efficacy of oral vs. topical, or combined oral and topical 5\u2011aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Am J Gastroenterol 107:167\u2013176","journal-title":"Am J Gastroenterol"},{"key":"1840_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/gut.47.3.410","volume":"47","author":"G Frieri","year":"2000","unstructured":"Frieri\u00a0G, Giacomelli\u00a0R, Pimpo\u00a0M et\u00a0al (2000) Mucosal 5\u2011aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 47:410\u2013414","journal-title":"Gut"},{"key":"1840_CR10","unstructured":"Gordon H, Minozzi S, Kopylov U et\u00a0al (2024) ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment. J\u00a0Crohns Colitis"},{"key":"1840_CR11","series-title":"Pharmacother","first-page":"1257","volume-title":"Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis","author":"V Gross","year":"2008","unstructured":"Gross\u00a0V (2008) Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis. Pharmacother, Bd. 9. Expert, Opin, S\u00a01257\u20131265"},{"key":"1840_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/gut.42.4.493","volume":"42","author":"V Gross","year":"1998","unstructured":"Gross\u00a0V, Andus\u00a0T, Ecker\u00a0KW et\u00a0al (1998) Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn\u2019s disease. The Budesonide Study Group. Gut 42:493\u2013496","journal-title":"Gut"},{"key":"1840_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2036.2005.02338.x","volume":"21","author":"S Hanauer","year":"2005","unstructured":"Hanauer\u00a0S, Sandborn\u00a0WJ, Persson\u00a0A, Persson\u00a0T (2005) Budesonide as maintenance treatment in Crohn\u2019s disease: a\u00a0placebo-controlled trial. Aliment Pharmacol Ther 21:363\u2013371","journal-title":"Aliment Pharmacol Ther"},{"key":"1840_CR14","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1111\/j.1572-0241.2005.00248.x","volume":"100","author":"SB Hanauer","year":"2005","unstructured":"Hanauer\u00a0SB, Sandborn\u00a0WJ, Kornbluth\u00a0A et\u00a0al (2005) Delayed-release oral mesalamine at 4.8\u202fg\/day (800\u202fmg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 100:2478\u20132485","journal-title":"Am J Gastroenterol"},{"key":"1840_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer\u00a0SB, Stromberg\u00a0U (2004) Oral Pentasa in the treatment of active Crohn\u2019s disease: A\u00a0meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2:379\u2013388","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1840_CR16","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1053\/j.gastro.2022.02.036","volume":"162","author":"J Hanzel","year":"2022","unstructured":"Hanzel\u00a0J, Ma\u00a0C, Jairath\u00a0V, Group IBDTD (2022) Design of Clinical Trials for Mild to Moderate Crohn\u2019s Disease. Gastroenterology 162:1800\u20131814","journal-title":"Gastroenterology"},{"key":"1840_CR17","first-page":"CD013210","volume":"9","author":"Z Iheozor-Ejiofor","year":"2019","unstructured":"Iheozor-Ejiofor\u00a0Z, Gordon\u00a0M, Clegg\u00a0A et\u00a0al (2019) Interventions for maintenance of surgically induced remission in Crohn\u2019s disease: a\u00a0network meta-analysis. Cochrane Database Syst Rev 9:CD13210","journal-title":"Cochrane Database Syst Rev"},{"key":"1840_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1053\/j.gastro.2006.10.011","volume":"132","author":"MA Kamm","year":"2007","unstructured":"Kamm\u00a0MA, Sandborn\u00a0WJ, Gassull\u00a0M et\u00a0al (2007) Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132:66\u201375","journal-title":"Gastroenterology"},{"key":"1840_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/jcag\/gwy018","volume":"1","author":"ME Kuenzig","year":"2018","unstructured":"Kuenzig\u00a0ME, Rezaie\u00a0A, Kaplan\u00a0GG et\u00a0al (2018) Budesonide for the Induction and Maintenance of Remission in Crohn\u2019s Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration. J\u00a0Can Assoc Gastroenterol 1:159\u2013173","journal-title":"J Can Assoc Gastroenterol"},{"key":"1840_CR20","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb\u00a0CA, Kennedy\u00a0NA, Raine\u00a0T et\u00a0al (2019) British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68:s1\u2013s106","journal-title":"Gut"},{"key":"1840_CR21","first-page":"CD008870","volume":"7","author":"WC Lim","year":"2016","unstructured":"Lim\u00a0WC, Wang\u00a0Y, MacDonald\u00a0JK, Hanauer\u00a0S (2016) Aminosalicylates for induction of remission or response in Crohn\u2019s disease. Cochrane Database Syst Rev 7:CD8870","journal-title":"Cochrane Database Syst Rev"},{"key":"1840_CR22","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1111\/j.1572-0241.2000.02180.x","volume":"95","author":"JK Marshall","year":"2000","unstructured":"Marshall\u00a0JK, Irvine\u00a0EJ (2000) Putting rectal 5\u2011aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 95:1628\u20131636","journal-title":"Am J Gastroenterol"},{"key":"1840_CR23","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/ibd.21838","volume":"18","author":"G Meucci","year":"2012","unstructured":"Meucci\u00a0G, Fasoli\u00a0R, Saibeni\u00a0S et\u00a0al (2012) Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a\u00a0prospective, multicenter study. Inflamm Bowel Dis 18:1006\u20131010","journal-title":"Inflamm Bowel Dis"},{"key":"1840_CR24","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/apt.13190","volume":"41","author":"L Moja","year":"2015","unstructured":"Moja\u00a0L, Danese\u00a0S, Fiorino\u00a0G et\u00a0al (2015) Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn\u2019s disease. Aliment Pharmacol Ther 41:1055\u20131065","journal-title":"Aliment Pharmacol Ther"},{"key":"1840_CR25","first-page":"CD000543","volume":"8","author":"A Murray","year":"2020","unstructured":"Murray\u00a0A, Nguyen\u00a0TM, Parker\u00a0CE et\u00a0al (2020) Oral 5\u2011aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 8:CD543","journal-title":"Cochrane Database Syst Rev"},{"key":"1840_CR26","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/S2468-1253(18)30231-0","volume":"3","author":"NH Nguyen","year":"2018","unstructured":"Nguyen\u00a0NH, Fumery\u00a0M, Dulai\u00a0PS et\u00a0al (2018) Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a\u00a0systematic review and network meta-analyses. Lancet Gastroenterol Hepatol 3:742\u2013753","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1840_CR27","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.dld.2013.07.006","volume":"45","author":"C Papi","year":"2013","unstructured":"Papi\u00a0C, Fasci-Spurio\u00a0F, Rogai\u00a0F et\u00a0al (2013) Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors. Dig Liver Dis 45:978\u2013985","journal-title":"Dig Liver Dis"},{"key":"1840_CR28","doi-asserted-by":"publisher","first-page":"456895","DOI":"10.1155\/2015\/456895","volume":"2015","author":"C Perrotta","year":"2015","unstructured":"Perrotta\u00a0C, Pellegrino\u00a0P, Moroni\u00a0E et\u00a0al (2015) Five-aminosalicylic Acid: an update for the reappraisal of an old drug. Gastroenterol Res Pract 2015:456895","journal-title":"Gastroenterol Res Pract"},{"key":"1840_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.crohns.2013.08.007","volume":"8","author":"CS Probert","year":"2014","unstructured":"Probert\u00a0CS, Dignass\u00a0AU, Lindgren\u00a0S et\u00a0al (2014) Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J\u00a0Crohns Colitis 8:200\u2013207","journal-title":"J Crohns Colitis"},{"key":"1840_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine\u00a0T, Bonovas\u00a0S, Burisch\u00a0J et\u00a0al (2022) ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J\u00a0Crohns Colitis 16:2\u201317","journal-title":"J Crohns Colitis"},{"key":"1840_CR31","first-page":"CD000296","volume":"2015","author":"A Rezaie","year":"2015","unstructured":"Rezaie\u00a0A, Kuenzig\u00a0ME, Benchimol\u00a0EI et\u00a0al (2015) Budesonide for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2015:CD296","journal-title":"Cochrane Database Syst Rev"},{"key":"1840_CR32","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3109\/00365528909090784","volume":"24","author":"MC Rijk","year":"1989","unstructured":"Rijk\u00a0MC, van Hogezand\u00a0RA, van Schaik\u00a0A, van Tongeren\u00a0JH (1989) Disposition of 5\u2011aminosalicylic acid from 5\u2011aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers. Scand J Gastroenterol 24:1179\u20131185","journal-title":"Scand J Gastroenterol"},{"key":"1840_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/00365528809093858","volume":"23","author":"MC Rijk","year":"1988","unstructured":"Rijk\u00a0MC, van Schaik\u00a0A, van Tongeren\u00a0JH (1988) Disposition of 5\u2011aminosalicylic acid by 5\u2011aminosalicylic acid-delivering compounds. Scand J Gastroenterol 23:107\u2013112","journal-title":"Scand J Gastroenterol"},{"key":"1840_CR34","volume-title":"Chronisch-entz\u00fcndliche Darmerkrankungen","author":"G Rogler","year":"2020","unstructured":"Rogler\u00a0G, Biedermann\u00a0L (2020) Klassifikationen, Indizes, Aktivit\u00e4tsbeurteilung. In: Hoffmann\u00a0JC et\u00a0al (Hrsg) Chronisch-entz\u00fcndliche Darmerkrankungen. Springer, Heidelberg"},{"key":"1840_CR35","first-page":"1867","volume":"92","author":"M Safdi","year":"1997","unstructured":"Safdi\u00a0M, DeMicco\u00a0M, Sninsky\u00a0C et\u00a0al (1997) A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92:1867\u20131871","journal-title":"Am J Gastroenterol"},{"key":"1840_CR36","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1111\/j.1572-0241.2005.41992.x","volume":"100","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn\u00a0WJ, Lofberg\u00a0R, Feagan\u00a0BG et\u00a0al (2005) Budesonide for maintenance of remission in patients with Crohn\u2019s disease in medically induced remission: a\u00a0predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 100:1780\u20131787","journal-title":"Am J Gastroenterol"},{"key":"1840_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.crohns.2013.03.005","volume":"8","author":"F Seibold","year":"2014","unstructured":"Seibold\u00a0F, Fournier\u00a0N, Beglinger\u00a0C et\u00a0al (2014) Topical therapy is underused in patients with ulcerative colitis. J\u00a0Crohns Colitis 8:56\u201363","journal-title":"J Crohns Colitis"},{"key":"1840_CR38","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1053\/j.gastro.2018.12.008","volume":"156","author":"S Singh","year":"2019","unstructured":"Singh\u00a0S, Feuerstein\u00a0JD, Binion\u00a0DG, Tremaine\u00a0WJ (2019) AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 156:769\u2013808","journal-title":"Gastroenterology"},{"key":"1840_CR39","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.2165\/0003495-200868170-00002","volume":"68","author":"K Wong","year":"2008","unstructured":"Wong\u00a0K, Bressler\u00a0B (2008) Mild to moderate Crohn\u2019s disease: an evidence-based treatment algorithm. Drugs 68:2419\u20132425","journal-title":"Drugs"},{"key":"1840_CR40","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/jgh.13604","volume":"32","author":"J Zeng","year":"2017","unstructured":"Zeng\u00a0J, Lv\u00a0L, Mei\u00a0ZC (2017) Budesonide foam for mild to moderate distal ulcerative colitis: A\u00a0systematic review and meta-analysis. J\u00a0Gastroenterol Hepatol 32:558\u2013566","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01840-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01840-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01840-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:29:32Z","timestamp":1737725372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01840-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1840"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01840-x","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"12 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Rogler gibt Beratung f\u00fcr AbbVie, Arena, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher,\nGenentech, Gilead, Janssen, Lilly, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions und\nZeller an; Vortragshonorare von AbbVie, AstraZeneca, BMS, Celgene, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots,\nUCB, Vifor und Zeller; Forschungsunterst\u00fctzung von AbbVie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD,\nNovartis, Pfizer, Roche, Takeda, Tillots, UCB and Zeller. G. Rogler ist Mitgr\u00fcnder und Miteigent\u00fcmer von PharmaBiome.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}